Holen Sie sich die Stockscreener-App
57.65
1.49%
-0.87
Handel nachbörslich:
57.73
0.08
+0.14%
Schlusskurs vom Vortag:
$58.52
Offen:
$58.52
24-Stunden-Volumen:
2.80M
Relative Volume:
0.92
Marktkapitalisierung:
$25.67B
Einnahmen:
$2.44B
Nettoeinkommen (Verlust:
$1.36B
KGV:
30.19
EPS:
1.9093
Netto-Cashflow:
$574.14M
1W Leistung:
-1.40%
1M Leistung:
-5.97%
6M Leistung:
+26.40%
1J Leistung:
+59.08%
1-Tages-Spanne:
$57.63
$59.02
1-Wochen-Bereich:
$57.63
$59.18
52-Wochen-Spanne:
$34.63
$64.38
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
57.65 | 26.06B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.53B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.82 | 82.77B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.11 | 72.88B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
945.82 | 60.30B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.00 | 41.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma PLC (RPD) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
RPRX: Strategic AI, scalable deal models, and China expansion drive robust, diversified growth - TradingView
Royalty Pharma PLC (RPD) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance Singapore
Royalty Pharma at Bank of America Global Healthcare Conference: growth even with policy risks - Investing.com
Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run - Yahoo Finance
Price-Driven Insight from (RPRX) for Rule-Based Strategy - Stock Traders Daily
Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns - Yahoo Finance
Andra AP fonden Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPD) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma (RPRX) holder plans new sale after selling 350,000 shares - Stock Titan
Royalty Pharma PLC (RPD) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma plc (RPRX) Stock Analysis: Exploring a 11.5% Potential Upside in the Biotech Royalty Space - DirectorsTalk Interviews
NewEdge Advisors LLC Raises Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Corient Private Wealth LP - MarketBeat
Could Royalty Pharma’s (NASDAQ:RPRX) Story Be Changing Fast? - Kalkine Media
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Is Royalty Pharma (RPRX) Below Fair Value After The Pelacarsen Trial Miss? - simplywall.st
A $7.5 million gift will help develop new blood cancer treatments - Stock Titan
California State Teachers Retirement System Decreases Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma at Morgan Stanley conference: growth broadens beyond royalties By Investing.com - Investing.com UK
WINTON GROUP Ltd Invests $1.28 Million in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by National Pension Service - MarketBeat
Tidal Investments LLC Has $6.63 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
(RPRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to Strong-Buy - MarketBeat
Engineers Gate Manager LP Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Squarepoint Ops LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to present at Morgan Stanley global healthcare investor conference - Bitget
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com Nigeria
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook By Investing.com - Investing.com South Africa
Royalty Pharma (NASDAQ:RPRX) Shares Gap DownWhat's Next? - MarketBeat
RPRX Maintained by TD Cowen -- Price Target Raised to $68.00 - GuruFocus
Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen - StreetInsider
TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Royalty Pharma PLC (RPRX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC $RPRX Position Increased by TD Waterhouse Canada Inc. - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Navigating Growth with a 16.5% Revenue Surge - DirectorsTalk Interviews
Royalty Pharma expects modest return despite pelacarsen trial failure By Investing.com - Investing.com Australia
Royalty Pharma Updates on Novartis' HORIZON Trial Results - Intellectia AI
Royalty Pharma expects modest return despite pelacarsen trial failure - investing.com
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen - manilatimes.net
Royalty Pharma Announces Novartis HORIZON Pelacarsen Trial Results and Updates Return Outlook on Ionis Funding Agreement - Quiver Quantitative
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):